Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium

Y. Morita, M. Yamamura, M. Kawashima, T. Aita, S. Harada, H. Okamoto, H. Inoue, Hirofumi Makino

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The purpose of this study was to compare the potential of interleukin-4 (IL-4), IL-10, and IL-13 to interrupt two major inflammatory pathways in rheumatoid arthritis (RA), i.e., overexpression of proinflammatory cytokines and cytokine-mediated fibroblast growth. IL-4, IL-10, and IL-13 were all able to significantly inhibit the production of IL-1β, tumor necrosis factor-α (TNF-α), IL-6, and IL-8 by freshly isolated RA synovial tissue cells; IL-10 was most effective in terms of IL-1β and TNF-α reduction. The IL-1 receptor antagonist was enhanced by IL-4 and IL-13, but only slightly enhanced by IL-10. Spontaneous interferon-γ secretion was diminished by IL-4 and IL-10 but not by IL-13. Addition of anti-IL-10 neutralizing antibody to RA synovial tissue cells resulted in a substantial increase in IL-1β and TNF-α levels, whereas neither anti-IL-4 nor anti-IL-13 antibody had a significant effect. IL-1β-stimulated proliferation of RA synovial fibroblast cell lines was inhibited by IL-4 and IL-13, but not by IL-10; IL-4 was over tenfold more effective than IL-13. These results suggest that IL-4, IL-10, and IL-13 all have the therapeutic potential to regulate the disease activity mediated by proinflammatory cytokines in RA, but each cytokine may have different potencies.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalRheumatology International
Volume20
Issue number2
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Interleukin-13
Synovial Membrane
Interleukin-4
Interleukin-10
Fibroblasts
Cytokines
Rheumatoid Arthritis
Interleukin-1
Tumor Necrosis Factor-alpha
Interleukin-1 Receptors
In Vitro Techniques
Neutralizing Antibodies
Interleukin-8
Interferons
Interleukin-6
Cell Line
Antibodies
Growth

Keywords

  • Anti-inflammatory cytokine
  • IL-10
  • IL-13
  • IL-4
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. / Morita, Y.; Yamamura, M.; Kawashima, M.; Aita, T.; Harada, S.; Okamoto, H.; Inoue, H.; Makino, Hirofumi.

In: Rheumatology International, Vol. 20, No. 2, 01.01.2000, p. 49-54.

Research output: Contribution to journalArticle

Morita, Y. ; Yamamura, M. ; Kawashima, M. ; Aita, T. ; Harada, S. ; Okamoto, H. ; Inoue, H. ; Makino, Hirofumi. / Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. In: Rheumatology International. 2000 ; Vol. 20, No. 2. pp. 49-54.
@article{441041c7ac664f1c811d8477ddd749f8,
title = "Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium",
abstract = "The purpose of this study was to compare the potential of interleukin-4 (IL-4), IL-10, and IL-13 to interrupt two major inflammatory pathways in rheumatoid arthritis (RA), i.e., overexpression of proinflammatory cytokines and cytokine-mediated fibroblast growth. IL-4, IL-10, and IL-13 were all able to significantly inhibit the production of IL-1β, tumor necrosis factor-α (TNF-α), IL-6, and IL-8 by freshly isolated RA synovial tissue cells; IL-10 was most effective in terms of IL-1β and TNF-α reduction. The IL-1 receptor antagonist was enhanced by IL-4 and IL-13, but only slightly enhanced by IL-10. Spontaneous interferon-γ secretion was diminished by IL-4 and IL-10 but not by IL-13. Addition of anti-IL-10 neutralizing antibody to RA synovial tissue cells resulted in a substantial increase in IL-1β and TNF-α levels, whereas neither anti-IL-4 nor anti-IL-13 antibody had a significant effect. IL-1β-stimulated proliferation of RA synovial fibroblast cell lines was inhibited by IL-4 and IL-13, but not by IL-10; IL-4 was over tenfold more effective than IL-13. These results suggest that IL-4, IL-10, and IL-13 all have the therapeutic potential to regulate the disease activity mediated by proinflammatory cytokines in RA, but each cytokine may have different potencies.",
keywords = "Anti-inflammatory cytokine, IL-10, IL-13, IL-4, Rheumatoid arthritis",
author = "Y. Morita and M. Yamamura and M. Kawashima and T. Aita and S. Harada and H. Okamoto and H. Inoue and Hirofumi Makino",
year = "2000",
month = "1",
day = "1",
doi = "10.1007/s002960000074",
language = "English",
volume = "20",
pages = "49--54",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium

AU - Morita, Y.

AU - Yamamura, M.

AU - Kawashima, M.

AU - Aita, T.

AU - Harada, S.

AU - Okamoto, H.

AU - Inoue, H.

AU - Makino, Hirofumi

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The purpose of this study was to compare the potential of interleukin-4 (IL-4), IL-10, and IL-13 to interrupt two major inflammatory pathways in rheumatoid arthritis (RA), i.e., overexpression of proinflammatory cytokines and cytokine-mediated fibroblast growth. IL-4, IL-10, and IL-13 were all able to significantly inhibit the production of IL-1β, tumor necrosis factor-α (TNF-α), IL-6, and IL-8 by freshly isolated RA synovial tissue cells; IL-10 was most effective in terms of IL-1β and TNF-α reduction. The IL-1 receptor antagonist was enhanced by IL-4 and IL-13, but only slightly enhanced by IL-10. Spontaneous interferon-γ secretion was diminished by IL-4 and IL-10 but not by IL-13. Addition of anti-IL-10 neutralizing antibody to RA synovial tissue cells resulted in a substantial increase in IL-1β and TNF-α levels, whereas neither anti-IL-4 nor anti-IL-13 antibody had a significant effect. IL-1β-stimulated proliferation of RA synovial fibroblast cell lines was inhibited by IL-4 and IL-13, but not by IL-10; IL-4 was over tenfold more effective than IL-13. These results suggest that IL-4, IL-10, and IL-13 all have the therapeutic potential to regulate the disease activity mediated by proinflammatory cytokines in RA, but each cytokine may have different potencies.

AB - The purpose of this study was to compare the potential of interleukin-4 (IL-4), IL-10, and IL-13 to interrupt two major inflammatory pathways in rheumatoid arthritis (RA), i.e., overexpression of proinflammatory cytokines and cytokine-mediated fibroblast growth. IL-4, IL-10, and IL-13 were all able to significantly inhibit the production of IL-1β, tumor necrosis factor-α (TNF-α), IL-6, and IL-8 by freshly isolated RA synovial tissue cells; IL-10 was most effective in terms of IL-1β and TNF-α reduction. The IL-1 receptor antagonist was enhanced by IL-4 and IL-13, but only slightly enhanced by IL-10. Spontaneous interferon-γ secretion was diminished by IL-4 and IL-10 but not by IL-13. Addition of anti-IL-10 neutralizing antibody to RA synovial tissue cells resulted in a substantial increase in IL-1β and TNF-α levels, whereas neither anti-IL-4 nor anti-IL-13 antibody had a significant effect. IL-1β-stimulated proliferation of RA synovial fibroblast cell lines was inhibited by IL-4 and IL-13, but not by IL-10; IL-4 was over tenfold more effective than IL-13. These results suggest that IL-4, IL-10, and IL-13 all have the therapeutic potential to regulate the disease activity mediated by proinflammatory cytokines in RA, but each cytokine may have different potencies.

KW - Anti-inflammatory cytokine

KW - IL-10

KW - IL-13

KW - IL-4

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0034467817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034467817&partnerID=8YFLogxK

U2 - 10.1007/s002960000074

DO - 10.1007/s002960000074

M3 - Article

C2 - 11269532

AN - SCOPUS:0034467817

VL - 20

SP - 49

EP - 54

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 2

ER -